WELL Health Launches Clinical Research Platform

WELL Health Technologies Corp., a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, has announced the launch of WELL Research, its consolidated clinical research brand. WELL Research offers a unique combination of full-service contract research organization (CRO) services in early-phase trials, site management organization (SMO) execution at late-stage trial sites, and bioanalytical services across every phase of clinical trials. Together, these capabilities span the full clinical trial value chain and allow sponsors and providers to enroll the right trial participants quickly and reliably.

WELL Research is supported by four of WELL's differentiated assets: Canada's largest outpatient clinic network, which comprises 275 clinics supporting over 5 million patient visits annually; WELLSTAR's provider network, which connects a network of over 45,000 healthcare providers; the WELLTrust patient consent platform, which has facilitated more than 100,000 patient consents; and HEALWELL AI's DARWEN™ platform for feasibility assessment and protocol-participant matching.

WELL Research comprises BioPharma Services Inc. (BPSI), a full-service CRO and bioanalytical laboratory with 20 years of operating history, and Canadian Phase Onward (CPO), its SMO, both held through the Company's clinical research joint venture with HEALWELL AI Inc. (HEALWELL).

WELL Health Technologies Corp., a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, has announced the launch of WELL Research, its consolidated clinical research brand. WELL Research provides full-service contract research organization (CRO) trial management for early-phase trials, site management organization (SMO) services for late-stage trial sites, and bioanalytical services across all phases of clinical trials. Together, these capabilities span the full clinical trial value chain and allow sponsors and providers to enroll the right trial participants quickly and reliably. WELL Research is supported by four of WELL's differentiated assets: Canada's largest outpatient clinic network, which comprises 275 clinics supporting over 5 million patient visits annually; WELLSTAR's provider network, which connects a network of over 45,000 healthcare providers; the WELLTrust patient consent platform, which has facilitated more than 100,000 patient consents; and HEALWELL AI's DARWEN™ platform for feasibility assessment and protocol-participant matching.